The nation of Zimbabwe has rejected a major American healthcare agreement valued at 367 million US dollars (272 million pounds) over five years due to the United States' insistence on sensitive information.
This rejection became public after a official document dated December was disclosed, which showed Head of State Emmerson Mnangagwa believed the agreement was "unbalanced".
An official spokesman has since clarified that the US was seeking genetic material for scientific study and profit while refused to guarantee the benefits from any future medical innovations.
"We must now begin the difficult and regrettable task of scaling back our support in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy indicated the US had furnished over $1.9bn for health programmes to Zimbabwe during the past two decades.
A doctors' association in Zimbabwe has appealed for further negotiations to reach a agreement suitable to all parties so the nation's vital HIV treatment initiative can proceed.
Broader Context
Zimbabwe's decision follows a similar case in Kenya, where a court blocked a similar deal with the US following concerns were raised about the safety of Kenyans' health data.
After returning to office recently, US President Donald Trump has slashed overseas assistance and shut down the US Agency for International Development (USAID).
USAID had administered assistance for the US government, but Trump argued its expenditure was "wasteful" and his administration was seeking government-to-government deals to enhance transparency and accountability.
According to statements, Sixteen African countries have so far agreed to these new health pacts, representing more than $18.3bn in new funding.
Details of the Declined Deal
The funds for Zimbabwe was intended to supported "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and disease outbreak preparedness.
"We are confident this partnership might have yielded extraordinary benefits for Zimbabwean communities, especially the 1.2 million men, women and children currently on HIV treatment via US-supported programmes," Tremont added.
However, official spokesman Nick Mangwana said the proposed deal was "asymmetrical".
"The proposal required Zimbabwe to share its biological resources and data indefinitely, with no equivalent promise of benefiting from any medical innovations – like new medicines or tests – that might be developed from that provided information," his statement read.
"In essence, our nation would provide the basic resources for medical research without any assurance that the resulting innovations would be available to our citizens should a future health crisis emerge."
National Interest and International Frameworks
Mangwana further said that the US's withdrawal from the World Health Organization (WHO) and its push of one-on-one health agreements were undermining structures already established via the international health agency.
Mangwana gave as an example its Pathogen Access and Benefit Sharing scheme designed to manage future global health emergencies.
"This framework is designed to guarantee that when a nation provides its data, the resulting advantages – including medicines and cures – are distributed fairly, not monopolised exclusively by those with the funds to create them."
Zimbabwe's reservations regarding the US deal "must not be interpreted as hostility towards the US," Mangwana stressed.
"We are open to further discussions with our American counterparts on how future co-operation might be structured in a way that respects the sovereignty and dignity of each country."
Medical Community Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) said it understood the official position, but urged that talks need to persist considering a large portion of the country's HIV programmes were funded by international support.
"In cases where specific concerns arise, such as those relating to information security or agreement terms, these can frequently be addressed via technical clarification and mutually agreed protections," it said.
The halted deal highlights the complex debate between receiving much-needed international aid and safeguarding national sovereignty in an ever more data-driven world.